Developing safe targeted Nucleic Acid Therapies

Nucleic Acid Therapies (NATs) are genetic medicines that can be used to treat diseases by directly targeting their causes. Genetic drugs can change the expression of genes and produce therapeutic effects which can be long-lasting or even provide a cure. A significant challenge in transforming healthcare with this promising category of therapeutic is in getting the drug to the organ, tissue and cell type in which it is needed. The TransNAT consortium has received funding of £8m for three years to improve the safe delivery of NATs to their targets. Its goal is to unlock the potential of programmable nucleic acid drugs via the expertise of a network of international academic and industrial partners.